Stimvia, a medical technology company specialising in neuromodulation for chronic disease treatment, has s pilot study focused on Parkinson’s Disease (PD) and is expecting promising results.
Twelve patients with Parkinson’s disease who met inclusion criteria participated in the study. For six weeks, patients used the URIS device for thirty-minute stimulation sessions daily. The URIS device operates on a principle of electrical transcutaneous nerve modulation (eTNM). Following this phase, patients went six weeks without stimulation, during which they continued to be monitored to assess whether any positive effects persisted after the treatment ended.
Since the URIS technology demonstrated a positive impact in treating Parkinson’s Disease, Stimvia plans substantial investment in further clinical trials to validate the method’s efficacy and safety.
The company envisions treating a significant number of people with PD using its unique technology in the near future. In the United States alone, an estimated 1 million individuals are affected by these conditions, contributing to over 10 million patients globally. Parkinson’s disease ranks as the second most prevalent neurodegenerative disorder after Alzheimer’s disease.